Shengtai Pharmaceutical Schedules 2008 Fourth Quarter And Year-End Financial Results and Conference Call
September 22 2008 - 12:10PM
PR Newswire (US)
WEIFANG, Shandong, China, Sept. 22 /Xinhua-PRNewswire-FirstCall/ --
Shengtai Pharmaceutical, Inc. (OTC:SGTI) (BULLETIN BOARD: SGTI)
("Shengtai Pharmaceutical" or "the Company"), a leading
manufacturer and distributor of high-quality, pharmaceutical grade
glucose products in China, today announced that it will issue
financial results for the three months and year ended June 30, 2008
after the close of the stock market on Monday, September 29, 2008.
Management will conduct a conference call on Tuesday, September 30,
2008 at 9:00 A.M. Eastern Daylight Time to discuss these results. A
question and answer session will follow management's presentation.
Mr. Qingtai Liu (Chief Executive Officer), Ms. Melody Shi (Chief
Financial Officer), and Ms. Michelle Wang (Investor Relations
Manager) will be the primary speakers on the call. A live webcast
of the conference call will be available on the Investor Relations
page of Shengtai Pharmaceutical's web site at
http://shengtaipharmaceutical.com/ . Please visit the Web site at
least 15 minutes early to register for the webcast and download any
necessary audio software. To participate, please call the following
numbers ten minutes before the call start time: Phone Number + 1
(877) 407-8035 (North America) Phone Number + 1 (201) 689-8035
(International) A replay of the call will be available through
Tuesday, October 7, 2008, at 11:59 P.M. Eastern Daylight Time/
Wednesday, October 8, 2008, 11:59 A.M. Beijing Time. For the
replay, please call: Phone Number +1 (877) 660-6853 (North America)
Phone Number +1 (201) 612-7415 (International) Account Number: 286
Conference ID Number: 297898 About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly owned subsidiary,
Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the
Chinese operating company of Weifang Shengtai Pharmaceutical Co.,
Ltd., is a leading manufacturer and supplier of pharmaceutical
grade glucose used for medical purposes. It also manufactures and
supplies glucose and cornstarch products to the food, beverage and
industrial production industries in China. For more information
about Shengtai Pharmaceutical, Inc., please visit
http://shengtaipharmaceutical.com/ . Safe Harbor Statement Safe
Harbor Statement under the Private Securities Litigation Reform Act
of 1995: Certain statements in this press release and oral
statements made by the Company constitute forward-looking
statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. These statements
include, without limitation, statements regarding our ability to
prepare the Company for growth, the Company's planned capacity
expansion in 2008 and predictions and guidance relating to the
Company's future financial performance. We have based these
forward-looking statements largely on our current expectations and
projections about future events and financial trends that we
believe may affect our financial condition, results of operations,
business strategy and financial needs, but they involve risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements, which may include,
but are not limited to, such factors as unanticipated changes in
product demand especially in the pharmaceutical industry, pricing
and demand trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large-scale implementation of the
Company's business plan, the ability to attract new customers,
ability to increase its product's applications, cost of raw
materials, downturns in the Chinese economy, and other information
detailed from time to time in the Company's filings and future
filings with the United States Securities and Exchange Commission.
Investors are urged to consider these factors carefully in
evaluating the forward-looking statements herein and are cautioned
not to place undue reliance on such forward-looking statements,
which are qualified in their entirety by this cautionary statement.
The forward-looking statements made herein speak only as of the
date of this press release and the Company undertakes no duty to
update any forward-looking statement to conform the statement to
actual results or changes in the Company's expectations. For more
information, please contact: Shengtai Pharmaceutical, Inc. Ms.
Melody Shi Chief Financial Officer Tel: +1-949-468-7078 Email:
Grayling Global Eddie Cheung Investor Relations Tel:
+1-646-284-9414 Email: DATASOURCE: Shengtai Pharmaceutical, Inc.
CONTACT: Company Contact, Ms. Melody Shi, CFO, Shengtai
Pharmaceutical, Inc., +1-949-468-7078, or ; Eddie Cheung, Investor
Relations, Grayling Global at +1-646-284-9414 or for Shengtai
Pharmaceutical Web site: http://www.shengtaipharmaceutical.com/
Copyright